慢性淋巴细胞白血病患者追加加强剂次可诱导与自然感染相似的SARS-CoV-2体液和细胞免疫应答,且与持续治疗无关:ERIC(欧洲CLL研究倡议)研究
研究比较慢性淋巴细胞白血病(CLL)患者加强针接种或突破性感染后的体液记忆和T细胞应答。加强剂次提高所有患者类别的血清转化率和抗体滴度,最终产生与感染后队列相似的体液应答;绝大多数患者(包括血清阴性者)产生T细胞应答,不同治疗组或接种与感染之间定性相似。
要点
- 加强剂次提高所有患者类别的血清转化率和抗体滴度,最终体液应答与感染后队列相似。
- 观察等待、停药缓解或维奈克拉单药治疗患者中超过80%出现超量程中位抗体滴度的体液应答。
- 抗CD20抗体和BTK抑制剂(BTKi)活动性治疗是体液应答的限制因素,但加强剂次或感染后约40%病例仍产生记忆。
核心结论
- 这些数据强调加强剂次在引发T细胞免疫方面的效力,且与治疗状态无关,并支持使用额外疫苗加强剂次以刺激接受活动性CLL定向治疗患者的体液免疫。
研究设计与样本
- 研究比较加强剂次接种或突破性感染后的体液记忆和T细胞应答。
主要发现
- 加强剂次提高所有患者类别的血清转化率和抗体滴度,最终产生与感染后队列相似的体液应答。
- 观察等待、停药缓解或维奈克拉单药治疗患者中超过80%出现超量程中位抗体滴度的体液应答。
- 抗CD20抗体和BTK抑制剂(BTKi)活动性治疗是体液应答的限制因素,但加强剂次或感染后约40%病例仍产生记忆。
- 绝大多数患者(包括血清阴性者)产生T细胞应答,不同治疗组或接种与感染之间定性相似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Profound immune dysregulation and impaired response to the SARS-CoV-2 vaccine put patients with chronic lymphocytic leukemia (CLL) at risk of severe COVID-19. We compared humoral memory and T-cell responses after booster dose vaccination or breakthrough infection. (Green) Quantitative determination of anti-Spike specific antibodies. Booster doses increased seroconversion rate and antibody titers in all patient categories, ultimately generating humoral responses similar to those observed in the postinfection cohort. In detail, humoral response with overscale median antibody titers arose in >80% of patients in watch and wait, off-therapy in remission, or under treatment with venetoclax single-agent. Anti-CD20 antibodies and active treatment with BTK inhibitors (BTKi) represent limiting factors of humoral response, still memory mounted in ~40% of cases following booster doses or infection. (Blue) Evaluation of SARS-CoV-2-specific T-cell responses. Number of T-cell functional activation markers documented in each patient. The vast majority of patients, including those seronegative, developed T-cell responses, qualitatively similar between treatment groups or between vaccination alone and infection cases. These data highlight the efficacy of booster doses in eliciting T-cell immunity independently of treatment status and support the use of additional vaccination boosters to stimulate humoral immunity in patients on active CLL-directed treatments.
引用
- Campanella A, Capasso A, Heltai S, et al. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL. Am J Hematol. 2024. PMID: 38264829. doi:10.1002/ajh.27218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。